China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety
BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device...
NMPA
China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management
The National Medical Products Administration (NMPA) of China has issued a new set of regulations...
China’s CDE Seeks Public Comment on Latest Generic Drug Reference Preparations
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) is currently...
China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals
The National Medical Products Administration (NMPA) of China has given the green light to Beijing...
China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs
In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...
China Expands Controlled Substances Catalogue to Include Three Additional Substances
The Ministry of Public Security, National Health Commission, and National Medical Products Administration in China...
NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...
China’s NMPA Unveils Three-Year Smart Supervision Plan for Blood Product Industry
China’s National Medical Products Administration (NMPA) has unveiled the “Three-Year Action Plan for Smart Supervision...
China’s NMPA Issues New Supervision Measures for Medical Device Clinical Trials Starting October 2024
The National Medical Products Administration (NMPA) has approved the “Measures for Supervision and Inspection of...
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate...
NMPA Releases 80th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 80th batch of reference drugs for...
China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023
The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...
China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation
The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...
ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...
CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures
The National Medical Products Administration (NMPA) of China has released a draft proposal for the...
NMPA Updates In Vitro Diagnostic Reagents Classification List for Enhanced Regulatory Oversigh
The National Medical Products Administration (NMPA) has coordinated the revision and release of the In...
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...
China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...